Rubedo Life Sciences expands its Scientific Advisory Board

Senescence-targeting biopharma bags Judith Campisi, Mario Lacouture and Francesca Grisoni.

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies for chronic age-related diseases targeting senescent cells that drive cellular aging, has announced the appointments of Judith Campisi, PhD, Francesca Grisoni, PhD, and Mario Lacouture, MD, to its Scientific Advisory Board (SAB). The SAB comprises experts in aging biology, AI, dermatology, drug discovery and development.

Longevity.Technology: Rubedo is developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases, so it makes strategic sense to build out its SAB. Rubedo’s proprietary ALEMBIC drug discovery platform engineers novel first-in-class small molecules which are designed to selectively target senescent cells; these play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.

“We are pleased to welcome Profs. Campisi, Lacouture and Grisoni, renowned experts in senescence, age-related diseases and AI drug discovery to Rubedo’s Scientific Advisory Board,” said Marco Quarta, PhD, Chief Executive Officer and Co-Founder of Rubedo Life Sciences.

“This depth of scientific expertise will be critical in advancing our pipeline of novel first-in-class small molecules that will target key drivers of progression in pulmonary, dermatological, oncological, and fibrotic diseases in the aging population [1].”

Longevity.Technology reached out to CEO Marco Quarta to discover more about Rubedo’s expansion strategy.

“We expanded SAB with Campisi and Lacouture to support the growth of Rubedo’s new therapeutics based on novel targets in additional indications part of our dermatology and liver programs, with novel lead compounds in optimisation,” he told us.

“On the other hand, Professor Grisoni joins the SAB to support the growth of ALEMBIC, implementing novel methods of computational deep learning modalities for single cell multi-Omics target discovery, as well as the downstream machine learning-based strategies for in silico small molecule drug development based on Rubedo’s chemistry-targeted strategies.”

The new members of Rubedo’s SAB include:

Judith (Judy) Campisi, PhD is a Professor at the Buck Institute for Research on Aging. She received a PhD in biochemistry from the State University of New York at Stony Brook and completed her postdoctoral training in cell cycle regulation at the Dana-Farber Cancer Institute and Harvard Medical School. As an assistant and associate professor at the Boston University Medical School, she studied the role of cellular senescence in suppressing cancer and became convinced of the contribution of senescent cells in the process of cellular aging. She joined the Lawrence Berkeley National Laboratory as a senior scientist in 1991 and in 2002, she started a second laboratory at the Buck Institute. At both institutions, Dr Campisi established a broad program to explore the relationship between aging and age-related disease, with an emphasis on the interface between cancer and aging. Dr Campisi is a member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.

Dr Campisi currently serves on advisory committees for the Alliance for Aging Research, Progeria Research Foundation, and NIA’s Intervention Testing Program. She is also an editorial board member for more than a dozen peer-reviewed journals. Dr Campisi is a scientific founder of Unity Biotechnology, a California-based company focused on developing therapies for age-related pathologies.

Mario E Lacouture, MD. Dr Lacouture is a Professor and the Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York City. He conducted his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his MD degree from Javeriana University in Bogota, Colombia, where he grew up. Dr Lacouture began his career in Oncodermatology at The University of Chicago. During his first faculty appointment at Northwestern University, Dr Lacouture received a Zell Scholarship and a Career Development Award from the Dermatology Foundation, and established the first clinical program focused on dermatologic care in cancer patients and survivors.

During this time, he initiated the first clinical trials in Oncodermatology, and described mechanisms and treatments on adverse events to novel cancer therapies, published in the Journal of Clinical Oncology and Nature Reviews Cancer. Dr Lacouture founded the Skin Toxicity and the Oncodermatology Study Groups of the Multinational Association of Supportive Care in Cancer, is on the Guidelines Advisory Committee of the American Society of Clinical Oncology, and the Editorial Board of Cancer.Net. Dr Lacouture has published over 280 articles in peer-reviewed journals and is the PI for numerous clinical trials aimed towards the treatment and understanding of adverse events to cancer therapies.

Francesca Grisoni, PhD, is an Assistant Professor at the Eindhoven University of Technology (Dept. Biomedical Engineering and Institute for Complex Molecular Systems), where she leads the Molecular Machine Learning team. Her research interests lie at the interface between machine learning and medicinal chemistry, aiming to develop novel computational tools to augment human intelligence in drug discovery. Francesca received her PhD from the University of Milano-Bicocca and worked as a data scientist and biostatistical consultant, and as a postdoctoral researcher at the ETH Zurich. Her work includes data-driven and AI-powered approaches for molecular property prediction, scaffold hopping, and de novo molecular design.

The new advisors will join existing SAB members, Cory Hogaboam, PhD, Paul Insel, MD, Lidia Schapira, MD, and Mark Pegram, MD.

Read more about Rubedo in our FREE Senotherapeutics report – CLICK HERE